Liver Diseases  >>  Locteron (interferon alpha-2b CR)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Locteron (interferon alpha-2b CR) / Biolex
480S, NCT00953589 / 2009-011182-86: 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)

Completed
2b
74
Europe, RoW
ribavirin, Ribasphere
Biolex Therapeutics, Inc.
Hepatitis C, Chronic
05/10
01/11
SELECT-2, NCT00863239 / 2008-007649-30: Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV

Checkmark DDW 2012
Apr 2011 - Apr 2011: DDW 2012
Checkmark EASL 2012
Mar 2011 - Mar 2011: EASL 2012
Completed
2b
116
US, Europe
ribavirin, Ribasphere®, Locteron™ (controlled-release interferon alpha 2b), Locteron, PolyActive, BLX-883, PEG-Intron™, 12 kDalton pegylated interferon
Biolex Therapeutics, Inc.
Hepatitis C, Chronic
11/10
11/11
PLUS, NCT00593151: Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

Completed
1/2
32
US
Locteron (controlled-release interferon alpha 2b), PolyActive-IFNa2b, BLX-883+PolyActive, pegylated IFNa2b, PEG-Intron, PEG, 12 kDalton pegylated interferon alpha 2b
Biolex Therapeutics, Inc.
Hepatitis C
12/08
03/09

Download Options